Acceleron

XLRN NASDAQ
42.89
+1.15
+2.76%
After Hours: 42.89 0 0.00% 16:53 07/18 EDT
Open
41.64
Prev Close
41.74
High
42.96
Low
41.64
Volume
175.07K
Avg Vol (3M)
304.34K
52 Week High
59.59
52 Week Low
37.01
% Turnover
0.33%
Market Cap
2.26B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Acceleron XLRN stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.
MORE >

Recently

Name
Price
%Change